0.25
+0.0028(+1.12%)
Currency In USD
| Previous Close | 0.25 |
| Open | 0.26 |
| Day High | 0.26 |
| Day Low | 0.24 |
| 52-Week High | 1.74 |
| 52-Week Low | 0.22 |
| Volume | 328,170 |
| Average Volume | 710,926 |
| Market Cap | 18.4M |
| PE | -0.34 |
| EPS | -0.74 |
| Moving Average 50 Days | 0.29 |
| Moving Average 200 Days | 0.59 |
| Change | 0 |
If you invested $1000 in IN8bio, Inc. (INAB) since IPO date, it would be worth $25.38 as of February 05, 2025 at a share price of $0.254. Whereas If you bought $1000 worth of IN8bio, Inc. (INAB) shares 3 years ago, it would be worth $77.61 as of February 05, 2025 at a share price of $0.254.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
IN8bio to Present at Biotech Showcase 2025 in San Francisco
GlobeNewswire Inc.
Jan 06, 2025 12:00 PM GMT
NEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will participate at Biotech Show
IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting
GlobeNewswire Inc.
Dec 10, 2024 12:00 PM GMT
INB-100 continues to demonstrate durable complete remissions (CR) with no relapses observed in any acute myeloid leukemia (AML) patients including those with high-risk disease after a median follow-up of 19.7 months. Data highlights INB-100’s long-te
IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference
GlobeNewswire Inc.
Dec 02, 2024 12:00 PM GMT
NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that William Ho, CEO and co-founder, will present at NobleCon20 -